Novartis Digital Strategy Dampens COVID-19 Impact
Stockpiling Brings $400m Q1 Sales Boost
The Swiss major says operations have not faced significant disruptions from the coronavirus pandemic but recruitment of patients for new trials, including a high-profile trial of inclisiran, have been impacted.
You may also be interested in...
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.